Here are three things to know:
1. Histogenics’ restorative cell therapy platform is designed to enhance the autologous cartilage repair process to produce functional living cartilage at the time of treatment.
2. The company’s first RCT product candidate, NeoCart, is intended to rebuild a patient’s own knee cartilage and may delay or prevent osteoarthritis.
3. Adam Gridley serves as president and CEO of Histogenics. He has more than 20 years of experience in the medical device, biotechnology and pharmaceutical industries.
More articles on biologics:
Imagion Biosystems incorporates ‘printer & ink’ business model for medical imaging
SpinalCyte receives additional patents: 3 takeaways
3 things to know about Lattice Biologics’ CEO
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
